You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Osteoporosis

Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

  • Technology appraisal guidance
  • Reference number: TA161
  • Published:  27 October 2008
  • Last updated:  07 February 2018
  • Guidance
  • Tools and resources
  • History

Osteoporosis - secondary prevention including strontium ranelate: Decision Support Unit (DSU) report

  • Osteoporosis - secondary prevention including strontium ranelate: DSU specification

  • Osteoporosis - secondary prevention including strontium ranelate: DSU report

  • Osteoporosis - secondary prevention including strontium ranelate: Servier response to DSU report


This page was last updated: 06 December 2010

Back to top